A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (HAL03T)

Eisai

Status: Completed

Conditions: Sarcoma, Soft Tissue

Treatments: Drug: Eribulin mesylate

Study type: Observational

Funder types: Industry

Identifiers

NCT03058406

E7389-M081-503

Details and patient eligibility

About

The purpose of this study is to understand safety and efficacy in participants with soft tissue sarcomas.

Enrollment: 256 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants with soft tissue sarcoma who will receive eribulin mesylate per the approved indication in routine clinical practice

Exclusion criteria

• None

Trial design

256 participants in 1 patient group

Eribulin mesylate

Treatment:

Drug: Eribulin mesylate